Publications by authors named "S Koole"
Article Synopsis
- Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in Stage III ovarian cancer after surgery, but optimizing patient selection is crucial to enhance treatment effectiveness and reduce unnecessary interventions.
- A study analyzed RNA sequencing data from 147 patients with high-grade serous ovarian cancer to identify biomarkers for HIPEC benefit, focusing on gene expression and tumor cell composition.
- The results suggested that the absence of macrophages and the presence of B cells in the tumor environment could predict HIPEC effectiveness, a finding supported by histological validation, indicating a need for further research on immune cell composition's role in treatment response.
Article Synopsis
- Various biomarker tests have been created to identify ideal candidates for PARP-inhibitor therapy but lack standardization, making it hard to assess their clinical value.
- The inconsistency in biomarker definitions, varying cutoff points, and unknown factors complicate treatment decisions.
- The article suggests aligning biomarker definitions and performance standards to promote fair access to precision medicine.
Article Synopsis
- - The study explored how family support impacts the mental health of Chinese college students during the early COVID-19 pandemic, finding that supportive family environments can help mitigate psychological distress.
- - Around 1,555 students evaluated their family dynamics and mental health, revealing that those with better family functioning reported fewer symptoms of depression and anxiety.
- - The findings suggest that stronger family ties can protect young adults' mental well-being during major crises, indicating the importance of family support in stressful times.
In the past decade, there have been a record number of oncology therapy approvals by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Besides the EMA's conditional marketing authorisation programme and the FDA's Accelerated Approval Program, we observe a tendency towards fast approval for exploratory studies with non-randomised, uncontrolled designs and surrogate endpoints. This issue raises concerns about the robustness and effectiveness of accepted treatments, leaving patients and health-care professionals in a state of uncertainty.
View Article and Find Full Text PDF